Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab in previously treated dMMR/MSI-H metastatic or recurrent colorectal cancer
CTR20192398Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in colorectal cancer (CRC), sponsored by Bristol Myers Squibb. Started Dec 2019; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20192398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192398.